Adamas Pharma Wins First FDA Nod for Parkinson's Drug

Aug 27, 2017

Reuters

The U.S. Food and Drug Administration approved Adamas Pharmaceuticals' Gocovri for treating a side effect caused by a popular Parkinson’s drug, according to a Reuters article. As a result, the company’s shares jumped 30.9 percent.

Many patients who struggle with Parkinson’s are treated with levodopa, but that often leads to dyskinesia, causing involuntary movements that are non-rhythmic, purposeless and unpredictable.

Gocovri, previously called ADS-5102, is said to be the first drug approved by the FDA to control levodopa-induced dyskinesia (LID).

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments